Literature DB >> 20582167

Metallomic profiling and linkage map analysis of early Parkinson's disease: a new insight to aluminum marker for the possible diagnosis.

Shiek S S J Ahmed1, Winkins Santosh.   

Abstract

BACKGROUND: Parkinson's disease (PD) is the most common neurodegenerative disorder. The diagnosis of PD is challenging and currently none of the biochemical tests have proven to help in diagnosis. Serum metallomic analysis may suggest the possibility of diagnosis of PD. METHODOLOGY/
RESULTS: The metallomic analysis was targeted on 31 elements obtained from 42 healthy controls and 45 drug naive PD patients using ICP-AES and ICP-MS to determine the concentration variations of elements between PD and normal. The targeted metallomic analysis showed the significant variations in 19 elements of patients compared to healthy control (p<0.04). The partial least squares discriminant analysis (PLS-DA) showed aluminium, copper, iron, manganese and zinc are the key elements, contributes the separation of PD patients from control samples. The correlation coefficient analysis and element-element ratio confirm the imbalance of inter-elements relationship in PD patients' serum. Furthermore, elements linkage map analysis showed aluminium is a key element involved in triggering of phosphorus, which subsequently lead to imbalance of homeostatic in PD serum. The execution of neural network using elements concentrations provides 95% accuracy in detection of disease.
CONCLUSIONS/SIGNIFICANCE: These results suggest that there is a disturbance in the elements homeostasis and inter-elements relationship in PD patients' serum. The analysis of serum elements helps in linking the underlying cellular processes such as oxidative stress, neuronal dysfunction and apoptosis, which are the dominating factors in PD. Also, these results increase the prospect of detection of early PD from serum through neural network algorithm.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20582167      PMCID: PMC2889819          DOI: 10.1371/journal.pone.0011252

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Parkinson's disease (PD) is a chronic neurodegenerative disorder, characterized by a progressive loss of substantia nigra pars compacta (SNc) neurons of unknown etiology [1]. The diagnosis of PD is entirely clinical with no biochemical tests presently available to diagnose PD. Current diagnosis is made by standard neurological examination and medical history. The severity of disease is categorized as stages based on the overall motor function evaluation using the Unified Parkinson's Disease Rating Scale (UPDRS) or Hoehn and Yahr scale or Schwab and England Activities of Daily Living Scale [2]. Three major cardinal symptoms of PD are tremor, rigidity and motor dysfunction, which significantly help in the detection of disease. However, the clinical diagnosis fails to identify the PD before the significant loss of dopamine neurons [3]. Hence, there is a need for early detection and more effective drugs to stop the progression of nigral degeneration [4]. Many decisions in medical practice are made by assessment of biomarkers. Biomarker serves as a diagnostic tool usually performed on body fluids, such as saliva, urine, serum or cerebrospinal fluid. Several studies suggest the diagnosis of PD from serum/plasma though the fundamental cause of disease is brain neurons [2], [5]. Metallomics approach is greatly focused on the detection of element markers for the diagnosis of diseases. Elements play a vital role in the biological system through their interaction with biomolecules. Elements regulate a number of cellular metabolic reactions, while a few of them act as etiological agents in many environmentally induced neurological disorders [6], [7]. Optimal concentration of elements is required for proper functioning of the human system. The deficiency of which causes serious metabolic abnormalities and increase leads to toxicity. The variations in serum elements can be potentially used for the diagnosis of diseases [8]. Several encouraging results were obtained using element analysis in an attempt to diagnose lung disease [9], hemochromatosis [10], chronic kidney disease [11], renal failure [12], cardiovascular disease [13] and liver disease [14]. In this study, an extensive analysis of 31 elements was made using inductive coupled plasma atomic emission spectroscopy (ICP-AES) and inductive coupled plasma mass spectroscopy (ICP-MS). The analysis was carried out on 42 normal and 45 drug-naive PD serum samples, to investigate the presence of variations in element concentrations of aluminium (Al), arsenic(As), barium (Ba), cadmium (Cd), calcium (Ca), cesium (Cs), chromium (Cr), cobalt (Co), copper (Cu), fluorine (F), iodine (I), iron (Fe), lead (Pb), mercury (Hg), magnesium (Mg), manganese (Mn), molybdenum (Mo), nickel (Ni), phosphorus (P), potassium (K), rubidium (Rb), selenium (Se), silicon (Si), silver (Ag), sodium (Na), strontium (Sr), sulphur (S), titanium (Ti), tungsten (W), vanadium (V) and zinc (Zn). The analysis was carried out on the early two stages of PD in order to determine the early diagnosis of disease. Also, the aim was to implement the concentrations of variable elements in artificial neural network (ANN) for early and rapid detection of PD. The results contribute to understand of metallomics dissimilarity patterns in PD compared to healthy control.

Results

Investigation of serum samples for the detection of element variations between normal and PD patients were performed using ICP-AES and ICP-MS. The analysis of spectra aimed for 31 trace and ultra trace elements (Ag, Al, As, Ba, Ca, Cd, Co, Cr, Cs, Cu, F, Fe, Hg, I, K, Mg, Mn, Mo, Na, Ni, P, Pb, Rb, S, Se, Si, Sr, Ti, V, W and Zn).The elements were selected based on the previous elements interaction study [15], in order to make the element linkage map for PD. The trace and ultra trace elemental concentrations were expressed in terms of microgram/deciliter (µg/dL). The comparative analysis revealed the variations in 22 elements. Silver (Ag), cadmium (Cd), cobalt (Co), iron (Fe), rubidium (Rb), sulphur (S), selenium (Se) and zinc (Zn) were decreased and increased aluminium (Al), calcium (Ca), chromium (Cr), copper (Cu), mercury (Hg), potassium (K), magnesium (Mg), manganese (Mn), molybdenum (Mo), sodium (Na), nickel (Ni), phosphorus (P), lead (Pb) and vanadium (V) was noticed in PD (Table 1). The concentrations of these elements were ranged from 0.0071 µg/dL for cadmium to 321000 µg/dL for sodium in PD samples. The observed values obtained in this study was expressed as the mean of 42 normal and 45 PD samples together with standard deviation (SD) (Table 1).
Table 1

Significant variations in element concentration.

ElementsConcentrations (µg/dL)
Reference ValueNormalDisease
Al--0.190±0.0080.32±0.07
Ag0.0180.017±0.0030.010±0.004*
Ca # 92508450±72010650±340
Cd--0.0119±0.00040.0071±0.006
Co--0.02±0.060.014±0.02
Cr--0.019±0.0020.028±0.003*
Cu7583±898±3
Fe119123±8110.4±0.6
Hg--0.136±0.0210.199±0.03
K # 1500014200± 80016300±300
Mg # 17501750±202009±43
Mn--0.061± 0.010.076±0.004
Mo0.150.09±0.050.19±0.02
Na# 312000309000±3400321000±1100
Ni--0.034±0.0050.044±0.003
P # 1190010800±120014700±1600
Pb--0.048±0.0030.069±0.002
Rb1715±301.7±0.7*
S--0.116±0.0030.104±0.002
Se1717±31.8±0.4
V--0.005±0.00010.009±0.0002
Zn6559±743±4

*In significance (p>0.05); # trace analysis carried out using ICP-AES; -- Data not available.

*In significance (p>0.05); # trace analysis carried out using ICP-AES; -- Data not available.

Statistical analysis

Analysis of variance (ANOVA) was performed to demonstrate the significance between the elements of control and PD (Table 1). In PD, Al, Cu, K, Mn, Mo, Na, P and V were increased significantly at p≤0.01 and Ca, Hg, Mg, Ni and Pb were increased significantly at p<0.05. The concentrations of Co, Fe, S, Se and Zn were decreased significantly at p≤0.01 and Cd was decreased significantly at p<0.05 in patient samples. The elements, Cr, Ag and Rb showed variations in concentrations with normal, were not attained the minimal significance of p≤0.05. The overall probability values of these 19 significant elements were ranged below 0.04 in PD serum compared to the control, which indicates the possible imbalance in elemental homeostasis.

Element classification analysis

To explore the elements multidimensional data, unsupervised PLS-DA method was executed. The PLS-DA analysis was carried out on 19 significant variable elements of 87 samples. The analysis showed a clear differentiation between healthy volunteers and drug-naive patients (Fig. 1). The loading coefficient map indicates Al, Cu, Fe, Mn and Zn were dominantly responsible for the separation of PD from normal (Fig. 2). Hence, the PLS-DA of elements confirms the likely importance of elevated Al, Cu and Mn and decreased concentrations of Fe and Zn for the diagnosis of PD.
Figure 1

PLS-DA analysis of normal and PD serum elements.

PLS-DA score's plot displays a significant separation between control subjects (n = 42) and unmedicated PD patients (n = 45) using complete digital maps. The observations coded according to class membership: triangle is normal and rhombus is PD. Each data point on a plot represents one individual.

Figure 2

Biomarker detection: Elements which are dominating the separation of disease from normal.

The loading coefficient map showing that aluminum, copper, iron, manganese, and zinc were predominantly responsible for the classification of groups. The blackened triangle represents elements; grey circle represents normal (N) and Parkinson's disease (P).

PLS-DA analysis of normal and PD serum elements.

PLS-DA score's plot displays a significant separation between control subjects (n = 42) and unmedicated PD patients (n = 45) using complete digital maps. The observations coded according to class membership: triangle is normal and rhombus is PD. Each data point on a plot represents one individual.

Biomarker detection: Elements which are dominating the separation of disease from normal.

The loading coefficient map showing that aluminum, copper, iron, manganese, and zinc were predominantly responsible for the classification of groups. The blackened triangle represents elements; grey circle represents normal (N) and Parkinson's disease (P).

Element inter- relationship

In order to bring out the inter-relationship between the major contributing elements, the element-element concentrations ratios was executed. The element-element ratios help to understand the interdependency of elements in the biological system. The results suggest that the ratios of Al/Cu, Al/Fe, Al/Mn, Al/Zn, Cu/Fe, Cu/Zn, Fe/Zn and Mn/Zn were increased and Fe/Mn and Cu/Mn were decreased in PD compared to healthy control (Table 2).
Table 2

Homeostatic imbalance of elements in comparison with control.

Elements XElements YElement ratio in normalElement ratio in PD
AlCu0.00220.0032
AlFe0.00130.0028
AlMn3.2454.210
AlZn0.00300.007
CuFe0.5970.864
CuMn14591289
CuZn1.362.27
FeMn24421492
FeZn2.2922.637
MnZn0.000930.0017

Linkage map analysis

The elements linkage map for PD was created using the correlation coefficient values of 18 significant elements with the understanding of previous elements interaction study [15]. Correlation coefficients were calculated using the concentrations (µg/dL) of 18 significant elements of PD. Implementation of PD correlation values in linkage map showed the variations in interaction pattern between Cu vs (Fe and Mo), P vs (Mn, Pb and Al), Se vs (Cu, Co and S), Zn vs (Pb, Fe and Ca), Ca vs Mg and Mn vs V in PD compared to previous elements interaction model (Fig. 3). In addition, few of the elements interactions are insignificant (p>0.05) in correlation analysis (Table 3).
Figure 3

Element linkage map representing the interactions of elements.

The interactions of 21 elements were configured. (A) Represents the basic interaction occurs in mammals. (B) Represents the interactions in PD. The single head arrow indicates the increase of an element X, decrease the element Y (negative correlation). The double headed arrow indicates, increase of an element X will increase the element Y or vice versa (positive correlation). The blackened arrow indicates similar significant patterns in (A) and (B); gray arrows indicate significant variations in interaction in PD and blackened dotted arrows indicate insignificant interaction. The grey box indicates insignificant variation in concentration between normal and disease (ANOVA), and their interactions analysis was not carried out.

Table 3

Element inter-relationship in PD for element linkage map.

Number of interactionElement XElement YDegree of correlation in PD
1CaMg0.234*
2CaP−0.789
3CuMo−0.397
4CuCd−0.802
5CuNi−0.973
6CuZn0.922
7CuCa−0.267*
8CuPb0.737
9CuFe0.289*
10CdCo−0.188*
11CdFe−0.802
12CdCa−0.359
13CdZn−0.970
14FeMn0.397
15FePb−0.433
16FeP−0.338*
17FeZn0.636
18FeCo0.866
19MnP0.729
20MnV0.0821*
21MnCa−0.155*
22PAl−0.957
23PbP0.994
24PbCa−0.848
25SMo−0.755
26SeCd−0.970
27SeCu0.636
28SeCo0.419
29SeHg0.090*
30SeS0.907
31ZnNi−0.986
32ZnPb0.419
33ZnCa0.124*

*Insignificance (p>0.05).

Element linkage map representing the interactions of elements.

The interactions of 21 elements were configured. (A) Represents the basic interaction occurs in mammals. (B) Represents the interactions in PD. The single head arrow indicates the increase of an element X, decrease the element Y (negative correlation). The double headed arrow indicates, increase of an element X will increase the element Y or vice versa (positive correlation). The blackened arrow indicates similar significant patterns in (A) and (B); gray arrows indicate significant variations in interaction in PD and blackened dotted arrows indicate insignificant interaction. The grey box indicates insignificant variation in concentration between normal and disease (ANOVA), and their interactions analysis was not carried out. *Insignificance (p>0.05).

ANN model and its diagnostic performance

The ANN model described in methodology was tested with 23 samples. The results were compared with known clinical status. The misclassification of one individual was noticed (Fig. 4). The success rate of the classification network was 95% (22/23) accuracy, whereas the specificity was 100% (11/11) and sensitivity was 91% (11/12). Furthermore, the values generated by the network are ranged from 0.1 to 1.0. Based on these values the individuals were assigned as normal or PD. The individuals whose final predicted values (x) ≤0.54 were assigned as normal and the values (x) ≥0.55 were assigned as PD.
Figure 4

Neural network predication.

Neural network classification of 23 individuals (x-axis) with known clinical information. Values (y-axis) are predicted over the trained network and are 0.1 to 1; values (x) ≤0.54 reflect a neural-network classification of “normal,” and values (x) ≥0.55 reflect a neural-network classification of PD. Individuals denoted by a triangle  =  normal, circle  =  PD and square  =  misdiagnosed individual.

Neural network predication.

Neural network classification of 23 individuals (x-axis) with known clinical information. Values (y-axis) are predicted over the trained network and are 0.1 to 1; values (x) ≤0.54 reflect a neural-network classification of “normal,” and values (x) ≥0.55 reflect a neural-network classification of PD. Individuals denoted by a triangle  =  normal, circle  =  PD and square  =  misdiagnosed individual.

Discussion

Neurodegeneration in PD is a complex and multifaceted process, affects a specific population of nerve cells. Elements play a crucial role in the pathogenesis of neurodegeneration [16]–[22]. Several studies suggest that there is an elemental variation in serum/plasma of PD [23]–[26]. However, there is an argument in levels of variation in elements among these studies, which may be due to a population variation. On understanding of those variations, this study was focused on 42 normal and 45 PD affected patients of South Indian population. The analysis was carried out on 31 trace and ultra trace elements in the prospective of diagnosis through neural-network algorithm. Targeted metallomic analysis of serum showed differential distribution of 19 elements in drug naive patients compared to the healthy control and reference elemental values (Table 1) [27]. Also, PLS-DA analysis showed Al, Cu, Fe, Mn and Zn are the key elements significantly contribute for the separation between the metallomics profiles of unmedicated PD patients and controls (Fig. 2). Moreover, it was hypothesized that increased Al concentration affects concentration of other elements by increasing the concentration of Cu, Na, K, P and Mn and decreasing the concentration of Fe, S, and Zn in serum [28]. Similar variation patterns were also exhibited in this study The serum Al level was significantly increased in PD patients. The Al concentration in our present investigation of control is 0.190 µg/dL and 0.32 µg/dL for PD. Al is a neurotoxin involved in Aβ aggregation, neuronal apoptosis and memory loss in animal model [29], [30]. The elevated serum Al concentration exhibits the clinical symptom of depression [28]. Increased Al was found to increase superoxide dismutase (SOD) activity to protect the cell from oxidative stress [31]. The increased SOD was previously reported in PD [32]. Furthermore, Al affects the integrity and functionality of mitochondria and endoplasmic reticulum (ER), which activates caspase-12 [33] that leads to endoplasmic mediated cell death [34]. Our results also demonstrate the increase Cu and decrease Zn. Similar trends were reported in schizophrenic, bipolar and unipolar patients [28], [35]–[38]. Cu is an essential element for the activity of cytochromeC oxidase, Cu/Zn superoxide dismutase and dopamine-beta-hydroxylase, which is critical in scavenging reactive oxygen species. The increased Cu generates reactive oxygen species which leads to oxidative stress and contributes to the cell death pathway [39]. Additionally, the serum Mn level was significantly increased in PD patients. Mn is associated with mitochondrial dysfunction and DNA fragmentation of primary striatal neurons [40]. The malfunctioning of mitochondria was reported [2] and DNA fragmentation mediated cell death was still unclear in PD. Our results demonstrate the decrease concentrations of Fe with increase concentrations of Al in PD serum. Interestingly, similar results were obtained in patients suffering from chronic fatigue syndrome which affects cognition and influences neurological abnormalities. Also, Fe plays a key role in oxidative stress [41] and readily reduces hydrogen peroxide to liberate the reactive and unselective hydroxyl radical, capable of inflicting severe oxidative damage [42]–[44]. H2O2 is freely permeable across membranes and readily inflicts oxidative damage to cells. Fe mediated increased radicals promote mitochondrial dysfunction, oxidative stress and neuron dysfunction [45]. Supportive of this finding, the animal experiment showed an association between reduced Fe and dopaminergic neurons [46]. Hence metallomics analysis of this study results in the imbalance of elements concentrations leads to biochemical changes such as oxidative stress, mitochondrial dysfunction and neuronal death in PD. This elemental imbalance in serum may reflex in the elemental concentrations of Zn, Al and Pb in the brain which have been implicated in the aggregation of alpha-synuclein, a crucial protein in Parkinson's disease [47]. Also, it is notable that there is an inter relationships between the elements that maintain the homeostasis of biological system. Moreover, the abnormalities of a single element concentration will affect the total element distribution pattern in the biological system. For instance, the results of element-to-element ratio of major contributing elements showed the increase in ratios of Al/Cu, Al/Fe, Al/Mn and Al/Zn in patients compared to control (Table 2). The abnormality in elemental ratios may be due to increase in Al, which disturbs the element homeostasis in serum by increasing the paramagnetic oxidant elements like Cu and Mn while decreasing Zn, an antioxidant metal required as a cofactor for CuZnSOD and Zn–thionein [28]. Furthermore, interdependency between the elements was validated using elements linkage map of previous study [15]. The elements linkage map of PD was created by implementing the significant correlation values of variable elements of PD in the linkage map model. Of 19 significant elements 18 were configured for linkage map analysis (Fig. 3). The element Na was excluded from the interaction study due to lack of interaction data in the model. The results show that the linkage map of previous model and PD patients were similar although there were variations in certain interaction pattern in PD patients. Nine significant variations in interaction patterns were noticed in PD (Fig. 3). Elements interaction between Cu vs Mo, P vs (Mn, Pb and Al), Se vs (Cu, Co and S) and Zn vs (Pb and Fe) were altered as shown in Figure 3. The interactions of F vs (Ca and Al) and Ti vs K were not measured due to the insignificant concentration of F and Ti in PD compared to healthy control. In consideration of the Al hypothesis in PD linkage map (Fig. 3), Al was observed to have interaction with F and P. However, there is no significant variation in concentration of F was noticed in PD compared to normal. Hence, it is understandable that Al involved in triggering of P in PD. Subsequently, P interacts with the Fe and Mn and altered their concentrations significantly. Furthermore, the concentrations of Cu and Zn may be altered by P via Pb. Also, the concentration variations in these Cu and Zn altered Se and its interacting elements. Hence, Al mediated interaction of P plays a vital role in the homeostasis of PD and increased serum Al concentration might be related with the risk of PD. The trace elements based diagnosis of PD was carried out using ANN. The results showed there is a misclassification of one diseased individual as normal (Fig. 4). The misclassification of this pathological condition may be due to the variable data of age and gender. The other variables of ANN were shown to be significant in ANOVA and PLS-DA. Hence, age and gender may be the major contributing factors for diagnosis. Few successful studies also showed the relation of gender and age with PD [48], [49]. However, the ANN diagnosis of PD provides 95% accuracy, which is more accurate than the current clinical diagnosis [2]. In conclusion, the present study of targeted metallomic profiling showed the significant abnormalities in 19 circulating elements, which help in linking the underlying cellular processes such as oxidative stress, neuronal dysfunction and apoptosis, the dominating factors in PD. Encouraging results were obtained in neural network for rapid detection of PD. Further work needs to be carried out in various populations to confirm the significance of the neural network in detection of PD. However, in present status it is suggested to execute a neural network along with a clinical diagnosis, which will additionally improve the accuracy of PD detection.

Materials and Methods

Sample collection

Clinical samples were collected from the out-patient setting of the Department of Neurology at SRM Hospital, Tamil Nadu, India. Drug-naive samples of 45 early PD patients were collected and 42 samples of age and gender-matched healthy controls were included for comparative study (Table 4). The written consent was obtained from each participant during in-person interview and blood donation. Data on gender, age, body mass index (BMI) and family history of PD were recorded. All individuals chosen for this study had no history of smoking, alcoholism, drug abuse and antioxidant treatment for a period of seven months before sample collection. The ethical committee of SRM Medical College Hospital & Research, India reviewed and approved the protocol of this study (Ref. No. 3496/Dean/07). The pathological status was well studied by a qualified neurologist and the disease stages were classified by UPDRS.
Table 4

Statistics of research participant's involved in study.

Sample informationNumber of samplesMean age in years±SDGender
MaleFemale
Normal4255.62±3.252517
PD 4557.62±9.102619

Collection and storage of samples

Blood samples were collected using intravenous canula from individuals and immediately centrifuged for five min at 14,000 rpm to separate serum from other cellular materials. Serum separations were carried out under HEPA filtered-air condition and tubes used were polypropylened and no glass material was used to prevent Al and Si contaminations. All precautions to eliminate metal contamination during blood collection and storage were taken in accordance with the National Committee for Clinical Laboratory Standards (NCCLS) criteria [50]. Subsequently, serum was transferred to fresh tube for the ICP-AES and ICP-MS preparation. The serum was digested with 0.5 ml conc. HNO3 and dried using a hot air oven. The dried serum was further dissolved with 5 ml of 0.1 M HNO3 solution containing Ge, Rh and Re as internal standard. This solution was immediately subjected to ICP-AES and ICP-MS to avoid contaminations.

ICP-AES and ICP-MS Instrumentation

The determination of Na, K, P, Ca and Mg in the serum samples was carried out using ICP-AES. The ultra trace elements were determined using ICP-MS instrument of Model SPQ8000A (Seiko Instruments, Chiba), equipped with quadruple mass spectrometer. The QA/QC of the instruments was performed to confirm and to validate test methodology including precision, accuracy and verifiable detection limits before the execution of analysis. Quality control was performed by analyzing a serum matrix matched multi-element synthetic standard and certified standard reference material obtained from the National Bureau of Standards, USA [51]. The instrumental and operating conditions are summarized in Table 5. The wavelengths of the emission line and mass numbers for the analyte elements were used in ICP-AES and ICP–MS for measurement, respectively. The lines were selected for each element in such a way that interference from the other elements was at minimum.
Table 5

The ICP instrumental and operating conditions.

Instrument parameterOptimization
ICP- AES
Gas Conditions
Carrier gasAr 18 l/min
Outer gasAr 1.03 l/min
Intermediate gasAr 0.57 l/min
Plasma conditions
Rf frequency27.12 MHz
Incident Rf power1 kW
Sampling conditions
Observation height18 mm above work coil
Sampling uptake rate1.1 ml/min
Torch Fassel type
Spray chamber Single type
Nebulizer Cross-flow type
ICP- MS Instrument
Gas Conditions
Carrier gasAr 16 l/min
Outer gasAr 1.04 l/min
Intermediate gasAr .95 l/min
Plasma conditions
Rf frequency27.12 MHz
Incident Rf power1 Kw
Sampling conditions
Sampling depth12 mm from work coil
Sampling uptake rate0.8 ml/min
Sampling coneCopper, 1.1 mm orifice diameter
Skimmer coneCopper, 0.35 mm orifice diameter
Data acquisition
Accumulation20 times
Dwell time10 ms/point
Repetition5 times
Channel width3 channels
Torch Fassel type
Spray chamber Scott type
Nebulizer Concentric type

Statistical analyses

The elements profiled data was imported into GeneSpring GX7.3 microarray software (Agilent Technologies Inc., Santa Clara, California), in which the analysis of variance (ANOVA) was performed. In order to confirm the biomarkers differentiating the patients from matched controls, PLS-DA was employed using Umatrices software (Umetrics, Inc., Kinnelon, NJ). The correlation coefficient and element-to-element ratios were calculated using Microsoft Excel 2003. The PD network map was created using the correlation coefficient values and mammalian network of previous study [15].

Artificial Neural network (ANN)

A NeuNet Pro software (CorMac Technologies Inc., Canada) was used for the ANN prediction. The ANN adopted in this study was three-layered network of back propagation algorithm. The input layer consisted of seven neurons (age, gender and concentrations of aluminium, copper, iron, manganese and zinc). The hidden layer, with six units, and an output layer, whose output values ranged from 0 to 1 indicating the likelihood of PD. The network was trained with variable data of randomly selected 64 individuals (31 normal and 33 PD) from the set of 87, with known pathological information. The training process continued until the difference between the ANN classification and clinical diagnosis became diminished. Once the network was trained, the remaining 23 individuals were tested using the trained network. The outcome of classification results was then compared to clinical data to determine the classification ability of the network.
  42 in total

1.  Age-related hippocampal changes in Bcl-2:Bax ratio, oxidative stress, redox-active iron and apoptosis associated with aluminum-induced neurodegeneration: increased susceptibility with aging.

Authors:  J Savory; J K Rao; Y Huang; P R Letada; M M Herman
Journal:  Neurotoxicology       Date:  1999-10       Impact factor: 4.294

2.  Abeta(1-42) and aluminum induce stress in the endoplasmic reticulum in rabbit hippocampus, involving nuclear translocation of gadd 153 and NF-kappaB.

Authors:  O Ghribi; M M Herman; D A DeWitt; M S Forbes; J Savory
Journal:  Brain Res Mol Brain Res       Date:  2001-11-30

3.  Serum concentrations of some metals and steroids in patients with chronic fatigue syndrome with reference to neurological and cognitive abnormalities.

Authors:  S J van Rensburg; F C Potocnik; T Kiss; F Hugo; P van Zijl; E Mansvelt; M E Carstens; P Theodorou; P R Hurly; R A Emsley; J J Taljaard
Journal:  Brain Res Bull       Date:  2001-05-15       Impact factor: 4.077

4.  Serum chemical elements and oxidative status in Alzheimer's disease, Parkinson disease and multiple sclerosis.

Authors:  Alessandro Alimonti; Giovanni Ristori; Franco Giubilei; Maria Antonia Stazi; Anna Pino; Andrea Visconti; Sonia Brescianini; Micaela Sepe Monti; Giovanni Forte; Paolo Stanzione; Beatrice Bocca; Giuseppe Bomboi; Cristina D'Ippolito; Viviana Annibali; Marco Salvetti; Giuseppe Sancesario
Journal:  Neurotoxicology       Date:  2006-12-09       Impact factor: 4.294

Review 5.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

6.  Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.

Authors:  X Huang; M P Cuajungco; C S Atwood; M A Hartshorn; J D Tyndall; G R Hanson; K C Stokes; M Leopold; G Multhaup; L E Goldstein; R C Scarpa; A J Saunders; J Lim; R D Moir; C Glabe; E F Bowden; C L Masters; D P Fairlie; R E Tanzi; A I Bush
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

7.  Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection.

Authors:  Shiek Ssj Ahmed; Winkins Santosh; Suresh Kumar; Hema T Thanka Christlet
Journal:  J Biomed Sci       Date:  2009-07-13       Impact factor: 8.410

Review 8.  Intracellular mechanisms underlying aluminum-induced apoptosis in rabbit brain.

Authors:  John Savory; Mary M Herman; Othman Ghribi
Journal:  J Inorg Biochem       Date:  2003-09-15       Impact factor: 4.155

9.  Serum copper in schizophrenia in Nigerians.

Authors:  D A Olatunbosun; M O Akindele; B K Adadevoh; T Asuni
Journal:  Br J Psychiatry       Date:  1975-08       Impact factor: 9.319

Review 10.  Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals.

Authors:  Maria Teresa Carrí; Alberto Ferri; Mauro Cozzolino; Lilia Calabrese; Giuseppe Rotilio
Journal:  Brain Res Bull       Date:  2003-08-30       Impact factor: 4.077

View more
  26 in total

1.  AMPK Inhibition Enhances the Neurotoxicity of Cu(II) in SH-SY5Y Cells.

Authors:  Ai-Ping Lan; Xian-Jia Xiong; Jun Chen; Xi Wang; Zhi-Fang Chai; Yi Hu
Journal:  Neurotox Res       Date:  2016-07-19       Impact factor: 3.911

2.  Aluminium exposure disrupts elemental homeostasis in Caenorhabditis elegans.

Authors:  Kathryn E Page; Keith N White; Catherine R McCrohan; David W Killilea; Gordon J Lithgow
Journal:  Metallomics       Date:  2012-04-26       Impact factor: 4.526

Review 3.  Coherent and Contradictory Facts, Feats and Fictions Associated with Metal Accumulation in Parkinson's Disease: Epicenter or Outcome, Yet a Demigod Question.

Authors:  Mohd Sami Ur Rasheed; Sonam Tripathi; Saumya Mishra; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2016-08-01       Impact factor: 5.590

4.  Brain-Delivery of Zinc-Ions as Potential Treatment for Neurological Diseases: Mini Review.

Authors:  Andreas M Grabrucker; Magali Rowan; Craig C Garner
Journal:  Drug Deliv Lett       Date:  2011-09

5.  Attenuation of Aluminum Chloride-Induced Neuroinflammation and Caspase Activation Through the AKT/GSK-3β Pathway by Hesperidin in Wistar Rats.

Authors:  Arokiasamy Justin-Thenmozhi; Mathiyazahan Dhivya Bharathi; Ramaraj Kiruthika; Thamilarasan Manivasagam; Anupom Borah; Musthafa Mohamed Essa
Journal:  Neurotox Res       Date:  2018-04-23       Impact factor: 3.911

6.  Ibuprofen targets neuronal pentraxins expresion and improves cognitive function in mouse model of AlCl3-induced neurotoxicity.

Authors:  Anum Jamil; Aamra Mahboob; Touqeer Ahmed
Journal:  Exp Ther Med       Date:  2015-12-10       Impact factor: 2.447

7.  PARK2 and PARK7 Gene Polymorphisms as Risk Factors Associated with Serum Element Concentrations and Clinical Symptoms of Parkinson's Disease.

Authors:  Jaya Sanyal; Athira Anirudhan; Tapas Kumar Banerjee; Gautam Guha; Ram Murugesan; S S J Shiek Ahmed; Vadlamudi Raghavendra Rao
Journal:  Cell Mol Neurobiol       Date:  2019-09-11       Impact factor: 5.046

8.  Manganese disturbs metal and protein homeostasis in Caenorhabditis elegans.

Authors:  Suzanne Angeli; Tracy Barhydt; Ross Jacobs; David W Killilea; Gordon J Lithgow; Julie K Andersen
Journal:  Metallomics       Date:  2014-07-24       Impact factor: 4.526

Review 9.  Synaptic Zinc: An Emerging Player in Parkinson's Disease.

Authors:  Joanna Sikora; Abdel-Mouttalib Ouagazzal
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

10.  Metal toxicity at the synapse: presynaptic, postsynaptic, and long-term effects.

Authors:  Sanah Sadiq; Zena Ghazala; Arnab Chowdhury; Dietrich Büsselberg
Journal:  J Toxicol       Date:  2012-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.